CDK4/6 Inhibitor Plus Camrelizumab for PD-1 Inhibitor Refractory R/M NPC
Because most patients with R/M NPC have received long-term maintenance of immunotherapy at the time of initial treatment and the first-line treatment, there are a large number of PD-1 inhibitor refractory patients. How to deal with the ICIs resistance is an urgent problem in clinical practice.
Nasopharyngeal Carcinoma
DRUG: Dalpiciclib Isetionate Tablets, Camrelizumab
Objective response rate (ORR), Objective response rate is the rate of patients achieving complete response or partial response for a certain period of time after intervention., 1 year
Median progression-free survival (PFS), Progression-free survival is defined as the time to the date of death of any cause or the first progress at any site, censored on the last date of tumor evaluation if no progress has happened., 1 year|Median overall survival (OS), Overall survival is defined as the time to the date of death of any cause, censored on the last date of known survival if no death has happened., 3 years|Duration of response (DoR), Defined as the time from first documentation of objective response to radiological disease progression, 1 year|Disease control rate (DCR), Disease control rate is the rate of patients achieving complete response, partial response or stable disease, 1 year|Incidence of adverse events, NCI-CTCAE 5.0 standard is adopted., 1 year
Because most patients with R/M NPC have received long-term maintenance of immunotherapy at the time of initial treatment and the first-line treatment, there are a large number of PD-1 inhibitor refractory patients. How to deal with the ICIs resistance is an urgent problem in clinical practice.